PER-028-21招募中4 期
MULTICENTER, RANDOMIZED, OPEN-LABEL TRlAL IN CHILDREN AND ADOLESCENTS TO ESTABLISH OPTIMAL NUMBER OF DOSES FOR HPV VACCINATION IN CHILDREN AND ADOLESCENTS LIVING WITH HIV
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •4.1.1 Arms 1 - 3: Children must be living with HIV. Hl V infection must be confirmed by local algorithm (positive NAAT test before 18 months of age with positive serologic test thereafter). Ann 4: Children must be healthy (without autoimmune disease or cancer) and not living with HIV.
- •4.1.2 Children in Anns 1 - 3 must be on a consistent, clinically appropriate combination ART regimen for >6 months prior to study enrollment.
- •4.1.3Children must be 9- 13-years-old (at or after 9lh birthday, prior to 14th birthday). This will allow us to vaccinate participants within the recommended age range for receipt of HPV vaccination in Peru and Brazil. Only children ages 9-11 (at or after 9th birthday, prior to 12u1birthday) will be enrolled into arm 3 and 4.
- •4.1.4 The most recent clinical laboratory values for children in Arms 1, 2, & 3 (CLWH) must be as described below: CD4 % > 15% or CD4 counts >200 cells/ mm3. VL (<400 copies/mL)
- •4.1.5 All female participants must not be pregnant (all females will receive pregnancy tests at all vaccine visits prior to receipt of study vaccine). The effects of Gardasil® 9 on the developing human fetus at the recommended therapeutic dose are unknown. If pregnancy is confirmed during the screening process, enrollment will not occur. If pregnancy occurs after the first vaccine dose, additional vaccine doses will not be administered, but the child will continue in follow-up.
- •4.1.6 We anticipate that all children will enter the study prior to sexual debut, although this will not be investigated clinically. Potential participants who report sexual activity will not be enrolled.
- •4.1.7 Children in all arms must have the ability to understand and the willingness to assent to the study. Parents or guardians must be able to understand and be willing to sign a written infomed consent document.
排除标准
- •4.2.1Children who ha ve a serious illness requiring treatment with systemic medications other than ART (excluding short course oral steroids or inhaled steroid treatment for asthma), are currently under immunomodulatory therapy, received immunosuppressive therapy (> IOmglday of prednisone or equivalent for > 1 week) in the 6 months prior to enrollment date.
- •4.2.2 Children who received any vaccine within 3 weeks prior to enrollment date (these children will be encouraged to enroll after 3 weeks have passed.
- •4.2.3 Children who received blood-derived products within 6 months prior to enrollment or planned use during the study period.
- •4.2.4 Children who weigh less than 18 kilograms.
- •4.2.5 Children with cancer being treated with thermotherapy or radiation.
- •4.2.6 Potential participants receiving any other investigational agents may be excluded in the opinion of the supervising physician.
- •4.2.7 Children in all anns with contraindications to vaccination, including pregnancy or breastfeeding
- •4.2.8 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •4.2.9 Children who are enrolled and later found to be seropositive for HPY at study entry (by Luminex assay performed by the Central Laboratory Core in Seattle) wil1 be discontinued from specimen collection.
- •4.2.10 History of allergic reactions attributed to compounds of similar chemical or biologic composition to HPY vaccination
研究者
相似试验
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic RO5534262 versus No Prophylaxis in Hemophilia A Patients with InhibitorsHemophilia A with InhibitorsMedDRA version: 18.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850MedDRA version: 18.0 Level: LLT Classification code 10053751 Term: Hemophilia A with anti factor VIII System Organ Class: 100000004850EUCTR2015-002866-21-ESRoche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.109
进行中（未招募）
1 期
oEUCTR2019-000990-22-NLGARDP FOUNDATIO1,092
进行中（未招募）
1 期
oEUCTR2019-000990-22-BEGARDP FOUNDATIO1,092
进行中（未招募）
1 期
This study examines the safety and efficacy of using ELAD treatment as a continuous liver support to a subject with liver failure secondary to acute hepatocellular insult and alcohol use, allowing time for the subject's native liver to recover and restore to a functional state. The study's primary objective is to evaluate ELAD safety and efficacy on overall survival through at least Study Day 91, with follow-up Protocol VTL-308E providing additional survival data up to a maximum of 5 years.EUCTR2015-004529-14-ESVital Therapies, Inc.150
进行中（未招募）
不适用
A MULTICENTRE,MULTINATIONAL, OPEN-LABEL, RANDOMISED, PARALLEL GROUP CLINICAL TRIAL OF TOBRINEB®/ACTITOB®/ BRAMITOB® (TOBRAMYCIN SOLUTION FOR NEBULISATION, 300 MG TWICE DAILY IN 4 ML UNIT DOSE VIALS) COMPARED TO TOBI® IN THE TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC INFECTION WITH PSEUDOMONAS AERUGINOSAcystic fibrosis and P. aeruginosa chronic infectionMedDRA version: 9.1Level: LLTClassification code 10057582Term: Lung infection pseudomonalMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2006-006215-68-HUChiesi Farmaceutici S.p.A320